Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)

Pays: Union européenne

Langue: croate

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

lenalidomide hydrochloride monohydrate

Disponible depuis:

Krka, d.d., Novo mesto 

Code ATC:

L04AX04

DCI (Dénomination commune internationale):

lenalidomide

Groupe thérapeutique:

imunosupresivi

Domaine thérapeutique:

Multiple Myeloma; Myelodysplastic Syndromes; Lymphoma, Follicular; Lymphoma, Mantle-Cell

indications thérapeutiques:

Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 i 5. Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 i 5. Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Descriptif du produit:

Revision: 4

Statut de autorisation:

odobren

Date de l'autorisation:

2021-02-11

Notice patient

                                93
B. UPUTA O LIJEKU
94
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
LENALIDOMID KRKA 2,5 MG TVRDE KAPSULE
LENALIDOMID KRKA 5 MG TVRDE KAPSULE
LENALIDOMID KRKA 7,5 MG TVRDE KAPSULE
LENALIDOMID KRKA 10 MG TVRDE KAPSULE
LENALIDOMID KRKA 15 MG TVRDE KAPSULE
LENALIDOMID KRKA 20 MG TVRDE KAPSULE
LENALIDOMID KRKA 25 MG TVRDE KAPSULE
lenalidomid
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se svom liječniku ili
ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Lenalidomid Krka i za što se koristi
2.
Što morate znati prije nego počnete uzimati Lenalidomid Krka
3.
Kako uzimati Lenalidomid Krka
4.
Moguće nuspojave
5.
Kako čuvati Lenalidomid Krka
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE LENALIDOMID KRKA I ZA ŠTO SE KORISTI
ŠTO JE LENALIDOMID KRKA
Lenalidomid Krka sadrži djelatnu tvar zvanu „lenalidomid“. Ovaj
lijek pripada skupini lijekova koji
utječu na način rada Vašeg imunološkog sustava.
ZA ŠTO SE KORISTI LENALIDOMID KRKA
Lenalidomid Krka se primjenjuje u odraslih za liječenje:
-
multiplog mijeloma
-
mijelodisplastičnih sindroma
-
limfoma plaštenih stanica
-
folikularnog limfoma
MULTIPLI MIJELOM
Multipli mijelom je vrsta raka koja pogađa određene vrste bijelih
krvnih stanica, zvane plazma stanice.
Te se stanice nakupljaju u koštanoj srži i dijele, ponašajući se
nekontrolirano. To može oštetiti kosti i
bubrege.
Multipli mijelom se općenito ne može izliječiti. Međutim, znakovi
i simptomi bolesti mogu se uvelike
smanjiti ili povući na neko vrijeme. To se naziva „odgovor”.
Novodijagnosticirani mul
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Lenalidomid Krka 2,5 mg tvrde kapsule
Lenalidomid Krka 5 mg tvrde kapsule
Lenalidomid Krka 7,5 mg tvrde kapsule
Lenalidomid Krka 10 mg tvrde kapsule
Lenalidomid Krka 15 mg tvrde kapsule
Lenalidomid Krka 20 mg tvrde kapsule
Lenalidomid Krka 25 mg tvrde kapsule
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna tvrda kapsula sadrži lenalidomidklorid hidrat u količini koja
odgovara 2,5 mg, 5 mg, 7,5 mg,
10 mg, 15 mg, 20 mg ili 25 mg lenalidomida.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Tvrda kapsula (kapsula)
Lenalidomid Krka 2,5 mg tvrde kapsule
Kapica kapsule je zelena, tijelo kapsule je zeleno s utisnutom crnom
oznakom 2.5. Sadržaj kapsule je
bijeli do žuto bijeli ili smeđe bijeli prašak. Veličina tvrde
kapsule: 4, duljina 14 ± 1 mm.
Lenalidomid Krka 5 mg tvrde kapsule
Kapica kapsule je plava, tijelo kapsule je plavo s utisnutom crnom
oznakom 5. Sadržaj kapsule je bijeli
do žuto bijeli ili smeđe bijeli prašak. Veličina tvrde kapsule: 2,
duljina 18 ± 1 mm.
Lenalidomid Krka 7,5 mg tvrde kapsule
Kapica kapsule je smeđa, tijelo kapsule je smeđe s utisnutom bijelom
oznakom 7.5. Sadržaj kapsule je
bijeli do žuto bijeli ili smeđe bijeli prašak. Veličina tvrde
kapsule: 1, duljina 19 ± 1 mm.
Lenalidomid Krka 10 mg tvrde kapsule
Kapica kapsule je zelena, tijelo kapsule je smeđe s utisnutom bijelom
oznakom 10. Sadržaj kapsule je
bijeli do žuto bijeli ili smeđe bijeli prašak. Veličina tvrde
kapsule: 0, duljina 21 ± 1 mm.
Lenalidomid Krka 15 mg tvrde kapsule
Kapica kapsule je smeđa, tijelo kapsule je plavo s utisnutom crnom
oznakom 15. Sadržaj kapsule je
bijeli do žuto bijeli ili smeđe bijeli prašak. Veličina tvrde
kapsule: 2, duljina 18 ± 1 mm.
Lenalidomid Krka 20 mg tvrde kapsule
Kapica kapsule je zelena, tijelo kapsule je plavo s utisnutom crnom
oznakom 20. Sadržaj kapsule je
bijeli do žuto bijeli ili smeđe bijeli prašak. Veličina tvrde
kapsule: 1, duljina 19 ± 1 mm.
Lenalidomid Krka 25 mg tvr
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 01-09-2021
Notice patient Notice patient espagnol 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 01-09-2021
Notice patient Notice patient tchèque 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 01-09-2021
Notice patient Notice patient danois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation danois 01-09-2021
Notice patient Notice patient allemand 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 01-09-2021
Notice patient Notice patient estonien 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 01-09-2021
Notice patient Notice patient grec 26-07-2023
Notice patient Notice patient anglais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation anglais 01-09-2021
Notice patient Notice patient français 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation français 01-09-2021
Notice patient Notice patient italien 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation italien 01-09-2021
Notice patient Notice patient letton 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation letton 01-09-2021
Notice patient Notice patient lituanien 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 01-09-2021
Notice patient Notice patient hongrois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 01-09-2021
Notice patient Notice patient maltais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 01-09-2021
Notice patient Notice patient néerlandais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 01-09-2021
Notice patient Notice patient polonais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 01-09-2021
Notice patient Notice patient portugais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 01-09-2021
Notice patient Notice patient roumain 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 01-09-2021
Notice patient Notice patient slovaque 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 01-09-2021
Notice patient Notice patient slovène 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 01-09-2021
Notice patient Notice patient finnois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 01-09-2021
Notice patient Notice patient suédois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 01-09-2021
Notice patient Notice patient norvégien 26-07-2023
Notice patient Notice patient islandais 26-07-2023

Rechercher des alertes liées à ce produit